Sign In
Buy NPCE
$15.88
-0.410 (-2.52%)
At Close: Jun 03, 2026
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation
09:30am, Tuesday, 03'rd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
09:00am, Tuesday, 03'rd Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. ("NeuroPace" or the "Company") (NASDAQ:NPCE). Such investors are ad
Lost Investment in NeuroPace, Inc. (NPCE)? Levi & Korsinsky Launches Securities Fraud Investigation
01:15pm, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of NeuroPace, Inc. - NPCE
12:47pm, Monday, 02'nd Jun 2025
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors a
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now
10:25am, Monday, 02'nd Jun 2025
NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
Bronstein, Gewirtz & Grossman, LLC Is Investigating NeuroPace, Inc. (NPCE) And Encourages Stockholders to Connect
10:00am, Monday, 02'nd Jun 2025
NEW YORK CITY, NY / ACCESS Newswire / June 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS
Fraud Investigation: Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) on Behalf of Shareholders
10:15am, Sunday, 01'st Jun 2025
NEW YORK, NY / ACCESS Newswire / June 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
NPCE ALERT: Ongoing Investigation Into NeuroPace, Inc. - Contact Levi & Korsinsky
11:00am, Friday, 30'th May 2025
NEW YORK, NY / ACCESS Newswire / May 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
Levi & Korsinsky Investigates NeuroPace, Inc. (NPCE) Over Possible Securities Fraud
01:15pm, Thursday, 29'th May 2025
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
Bronstein, Gewirtz & Grossman, LLC Encourages NeuroPace, Inc. (NPCE) Investors to Inquire about Securities Investigation
12:45pm, Thursday, 29'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of NeuroPace, Inc. ("NeuroPace" or "the Company") (NAS
NPCE ACTIVE INVESTIGATION: Lost Money on NeuroPace, Inc.? Contact Levi & Korsinsky Now
11:15am, Thursday, 29'th May 2025
NEW YORK, NY / ACCESS Newswire / May 29, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of NeuroPace, Inc. ("NeuroPace, Inc.") (NASDAQ:NPCE) concerning possible viol
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
06:31pm, Wednesday, 28'th May 2025
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors ar
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
12:50pm, Wednesday, 28'th May 2025
NeuroPace reports promising one-year results from its NAUTILUS trial, showcasing the RNS System's effectiveness in treating idiopathic generalized epilepsy with sustained seizure reduction.
Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?
12:48pm, Tuesday, 27'th May 2025
NeuroPace, Inc. NPCE released preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for drug-resistant idiopathic generaliz
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
08:00am, Tuesday, 27'th May 2025
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy
